Economy Secretary Keith Brown announced the planned creation of 43 new jobs by Glasgow-based BioClavis as part of a £10.5 million investment supported by Scottish Enterprise.
Bioclavis is a new spin-out from Californian molecular profiling company Biospyder which will be based at the Clinical Innovation Zone at Glasgow’s Queen Elizabeth University Hospital.
BioSpyder’s investment has been supported by a £4.5 million Seek & Solve research and development grant from Scottish Enterprise.
It forms part of a total investment of £10.5 million which will see BioClavis adapt BioSpyder’s TempO-Seq platform technology into a novel diagnostic tool for precision medicine in a number of high value clinical indications — in close collaboration with the health service and university researchers.
Brown said: “This is an exciting time for life sciences businesses in Scotland.
“The sector is strong and continuing to grow — providing employment for over 37,000 people.
“This Government has worked hard to enhance Scotland’s growing reputation as a global centre of excellence for clinical research.
“Today’s announcement is evidence of this and I’m delighted that Biospyder has chosen to base its new spinout, Bioclavis, in Scotland, where it will take forward a new project in precision medicine with our health service and universities.”
Joel McComb, CEO of BioSpyder and BioClavis said: “We’re very excited to build on the success we’ve had in other molecular profiling applications and bring this novel method to bear on discovery and deployment of next generation genomic diagnostics.
“We determined Glasgow, Scotland to be the ideal location for this initiative based in large part on the support and close working relationships with ScottishEnterprise, NHS and the University.”